Get started

Biotech

$PFE Key Levels, Analysis, & Targets $PFE Key Levels, Analysis, & Targets Swing setup 1 at 47.59 1 at 45.65 2 at 41.06 4 at 38.36 8 at 34.40 (Then multiply by your multiplier (x5, x10, x100, x1000, etc to find your position size) Looking for 15%, up to 20% if all targets hit… --- I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading. IF you need anything analyzed Technically just comment with the Ticker and I’ll do it as soon as possible…
NYSE:PFEShort
by SPYder_QQQueen_Trading
NTLA Intellia Therapeutics Inc. BPC Chart Overview 03/28/22Intellia Therapeutics Inc. NASDAQ: NTLA Chart Overview 03/28/22 Intellia is trading in a 9-month downward channel pullback, closing the gap created by the release of Phase 1 data of NTLA-2001 to treat ATTR. The release caused a bull pennant that led to a reversal into a downward channel. We are tracking support at $56 and a resistance line is at $90. The downward channel pullback may be forming a descending wedge, which could lead to a bullish breakout. Tracking RSI and MACD, the lowest lows on both charts are displaying a slight increase, running opposite to price, which lowest lows are continuing to decrease. The bullish divergence also indicates a possible breakout if met with an increase in volume. Good news could mean that the recent bottom is in, possible clinical holds, or other issues could test 2021 lows around $44. We will be looking for a breakout over $90 into a new bullish pattern. Intellia will be commencing Part 2 of its NTLA-2001 and is set to read out from its Phase 1/2 NTLA-2002 hereditary angioedema (HAE) trial this year. A recent loss in a CRISPR patent ruling increases uncertainty in the stock. Catalysts can have a profound effect on stock price and incorporating BioPharmCatalyst into your due diligence can ensure that you are prepared. Track 1000+ catalysts and access over 800+ companies’ fundamentals, earnings and analyst ratings by becoming a BPC Premium Subscriber. Sign up for your FREE trial at www.biopharmcatalyst.com Get a daily breakdown of biotech investor news straight to your inbox with our pre and post market newsletters sign up here www.biopharmcatalyst.com
NASDAQ:NTLA
by BioPharmCatalyst
BCTX BriaCell Therapeutics Corp: BPC Chart Overview 03/28/22BriaCell Therapeutics Corp. NASDAQ: BCTX Chart Overview 03/28/22 BriaCell broke out of a 3-month downward channel into an upward channel. We are tracking support lines at $4.20, $5, and $5.89, and resistance lines at $9.60 and $10.47. Friday and today shares are trading overextended and coming up to resistance both in terms of channel lines, candlesticks, resistance price at $6.90. Shares are currently trading above the 1st resistance at $9.60, and we will be watching changes in volume to confirm the breakout. Through utilizing the Stochlistics chart, it appears that the price is overbought and a possible indicator of a return to the pattern. If the channel holds then we will look to retest the $6.90 resistance to see if it breaks out and moves higher into new recent highs. Track 1000+ catalysts and access over 800+ companies’ fundamentals, earnings and analyst ratings by becoming a BPC Premium Subscriber. Sign up for your FREE trial at www.biopharmcatalyst.com Get a daily breakdown of biotech investor news straight to your inbox with our pre and post market newsletters sign up here www.biopharmcatalyst.com
NASDAQ:BCTX
by BioPharmCatalyst
Elevation Oncologys personalised treatment plans for cancer ⚕️I find that the cash ($146M) vs valuation (55M) is rocket fuel for “the herd”. Also presenting itself as an “undiscovered gem” may contribute to a good ol’ pop. They have good social media skills and their website is gorgeous. Being that this will be about as much DD as the masses ever do it can and most times is quite important for fueling said pop. RSI in the low lows lends a little more to the “undiscovered gem” ideology even though I loath technical analysis many do not. News about their phase II study (which they seem to be taking very seriously) should come to light within the following months and as any biotech investor knows: news + biotech = insane short term gains. Check out my ideas on Utradea
NASDAQ:ELEVLong
by Magnus_Chimpski
Miromatrix and their bioengineered pig-human hybrid organs 🐷The set up for a pump seems to be falling nicely into place, cheap, small cap, descent into oblivion, interesting tech, “undiscovered gem” feeling. The volume is dastardly and it could still fall sub $2 before making a comeback. They may pull a card out of their sleeve tomorrow at CareDx’s Xenotransplantation Innovation Day however it seems unlikely. It is probably a better idea to wait for news on the initiation of the phase I trials for their external liver assist program. Around that time if there is an uptick in social media buzz we may very well be in for a good ol’ pump, probably followed by an offering to fill the coffers if the stock price gains permit.
M
by Magnus_Chimpski
Long The High Risk Psilocybin Mushroom Therapy Secular Bull RunNot looking for an immediate turn around because Macro-Market conditions and retail risk tolerance is severely negative right now. However, this sector has huge potential to be a bullish meme in years ahead. Think of getting into Pot Stocks 2.0 before the moon pumps In 2018–19, the United States Food and Drug Administration (FDA) granted breakthrough therapy designation to facilitate further research for psilocybin in the possible treatment of depressive disorders. As of 2020, research on the use of psilocybin indicated it caused hallucinations with inability to establish reality from fantasy, panic reactions, and possible psychoses at high doses. In November 2020, the U.S. state of Oregon legalized psilocybin for people age 21 and older, and decriminalized possession or use of psilocybin mushrooms for medical conditions, such as depression, anxiety, or PTSD.
FLong
by noam_chom
2
Allarity priming itself for a pumpAs with most micro biotech companies, I expect the price to continue to fall to the $1 region and then “flatten out” for a while to keep its head just above the minimum listing requirement. It will then probably remain there until it is seemingly forgotten. Then, in a move to regain compliance (if it falls below $1) we can expect some financial reorganisation on the stocks behalf and possibly a R/S on the cards if things get dire. If it remains over the minimum listing price, I expect some group of pumpers to catch on to Allarity and we could see a few weeks of growing buzz on social media platforms, followed by some handy articles and a sudden parabolic move upwards on news as FOMO kicks in to the herd.
NASDAQ:ALLR
by Magnus_Chimpski
Biotechnology is the next sector to have big runnersI'm looking at Biotechnologies and healthcare sector for my next sector that is going to run beyond the oil industry. Oil is going to die down in the next week or two because the Biden admin will want that to go hush hush. I estimate we will still have one or two more really rallies in the oil industry before we see the whole sector of biotech go nuts. Again just a prediction. I'm broker than the next guy in stocks so follow me if you want to run into crazy stuff. BCEL is my pick as a great potential for the sector move. It has volume, a low float and looks like it's setting up for crossing over the 200 ma. I don't really like to make those trades before they cross over the 200ma because they haven't officially broken the trend until they are over the 200 ma and sustain it, but BCEL may be a good short term play.
B
by thephysicsguy1
$XBI Key Levels, Analysis & Targets - Request$XBI Key Levels, Analysis & Targets - Request Ok, @FlashingGraphs so these would be my targets fo XBI. It sounds like you don’t have an open position yet… I would start around 78.06. Then if it keeps selling off, then double your position at 62.94 And if it still continues then double again at 45.89. If those 3 hit then you can expect a solid 50% swing from there… Because of the way the Biotech sector moved in the past two years I could definitely see it making a 3 standard deviation move down like this, in correction. Don’t go in too heavy until you see a clear reversal sign… (such as macD crossing back above 0, and consistent higher lows) And with that being said I still would start building from Target 1. I hope this helps. GL & happy swinging…
AMEX:XBIShort
by SPYder_QQQueen_Trading
2
SBFM - Sunshine Biopharma Doing BIG Things!Always DYOR and understand the dynamics of these OTC stocks (known for pump & dump) but the fundamentals here are what will ultimately drive Sunshine Biopharma to return to it's formerly glorious highs but for now, it's relegated to the fractional levels that we see. On it's face, it looks like a no-brainer . . company shedding debt, increasing earnings (still no real profitability) BUT, a recent patent publication and a litany of amazing solutions in the areas of drug-resistant cancers, COVID-19, etc. But don't take my word for it . . check it out . . sunshinebiopharma.com Caveat Emptor - The evil corporate empire will probably try to keep this one squashed and on the DL with massive shorting (if I had to guess) and for several reasons 1. Competition 2. Cancer is big business and people that cure it tend to go away quickly 3. Keep the price low with the help of WS peckerwoods for a cheaper acquisition Again, I don't render professional investment advice, I just read charts and try to tie the fundamentals into a more complete picture. The Fib channel looks attractive in an uptrend, we just got a nice bump up above the 50/200 EMA and we know what kind of price history this beauty has so it's worth an add. I've got a DCA bag and will LTBH it for either a buyout or until the WS woods drive it to zero, whatever the outcome . . no risk, no reward. Good luck!
SLong
by FudBox
8
Up tnend startThe stock broke through resistance and went to close the gap. The global target is $24. Upside +50%. Trade with a trailing stop. ❤️ If you find this helpful and want more FREE forecasts in TradingView . . . . . Please show your support back, . . . . . . . . Hit the 👍 LIKE button, . . . . . . . . . . . Drop some feedback below in the comment! ❤️ Your Support is very much 🙏 appreciated!❤️ 💎 Want us to help you become a better Stock trader? Now, It's your turn! Be sure to leave a comment let us know how do you see this opportunity and forecast
NASDAQ:FGENLong
by QuantumLabSignals
2
ATOS Weekly Shaping UpWe can see that the weekly chart is showing some exhaustion on the sell pressure. The daily has a bit of a heartbeat today breaking over the 20ema/ma. Looking to see the weekly SARs flip underneath to support price, and a break over the T Line (EMA8) on the weekly to confirm a trend change. If there is a solid break, targets (based on current price but will change) would be: Weekly 20ema - 2.04 Weekly 50ema - 2.53 Weekly 100ema - 3.24 Anything over would just be cream. Unless they finally go phase 3 for endoxifen, but I'm sticking to TA.
NASDAQ:ATOSLong
by DrDank
1
$ARDS Target PTs 4.30-6 and higherH.C. Wainwright Bullish on Aridis Pharmaceuticals Covid-19 Antibody Cocktail Aridis Pharmaceuticals CEO Discusses Monoclonal Antibody Cocktail Protection Against COVID-19 Omicron Variant and Other Viruses in Fox Business Interview LOS GATOS, Calif., Dec. 21, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that Vu Truong, Ph.D., Chief Executive Officer, was interviewed on Varney & Co., hosted by Stuart Varney, on Fox Business. Key Highlights: AR-703, one of the components of the AR-701 cocktail, binds to the 'S2' stalk region of coronavirus spike proteins that is responsible for viral fusion and entry into host cells, and binds to the Omicron variant with no loss in affinity as compared to the original Wuhan strain. In vitro neutralization studies using live coronaviruses showed that AR-701 achieved broad, potent neutralization against all SARS-CoV-2 variants tested, as well as SARS, MERS, and the seasonal 'common cold' betacoronaviruses. In vivo data with multiple animal challenge models that are widely used to evaluate COVID-19 treatments support AR-701's broad efficacy. AR-701 is engineered to be long-acting and is expected to provide relevant drug levels for up to 1 year from prophylactic or therapeutic treatment. Watch the full interview: video.foxbusiness.com About AR-701 AR-701 is a cocktail of two fully human immunoglobulin G1 (IgG1) mAbs discovered from screening the antibody secreting B-cells of convalescent SARS-CoV-2 infected (COVID-19) patients. AR-701 consists of AR-703 and AR-720 mAbs, each neutralizes coronaviruses using distinct mechanisms of action, namely inhibition of viral fusion and entry into human cells (AR-703) and blockage of viral binding to the human 'ACE2' receptor (AR-720). The two mAbs complement and enhance each other in a synergistic fashion, creating a potent first-in-class cocktail. AR-703 binds to the 'S2' stalk region of spike proteins from betacoronaviruses, including the SARS-CoV2 variants (beta, gamma, delta, epsilon), and binds to the Omicron variant with no loss in affinity compared to the original Wuhan strain. Multiple animal challenge models widely used to evaluate COVID-19 treatments support AR-701's broad efficacy, including: AR-701 mAbs administered parenterally, either individually or in combination with one another, eradicated SARS-CoV-2 (Wuhan strain) from the lungs of infected mice. Hamsters infected with the SARS-CoV-2 (Delta variant) and later treated once with inhaled AR-701 mAbs, either individually or in combination, were protected from disease and weight loss. Mice infected with the Severe Acute Respiratory Syndrome virus (SARS) were also protected from disease and weight loss with a single inhaled dose of AR-701. The AR-701 mAbs are engineered to be active for 6-12 months in the blood. AR-701 is being developed as a long-acting intramuscular as well as a self-administered inhaled formulation for the treatment of COVID-19 patients who are not yet hospitalized. AR-701 mAbs were discovered through a collaboration with researchers at the University of Alabama in Birmingham and Texas Biomedical Research Institute (San Antonio, TX). About Aridis Pharmaceuticals, Inc. Aridis Pharmaceuticals, Inc. discovers and develops novel anti-infective therapies to treat life-threatening infections, including anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary ʎPEXTM and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality. The Company is advancing multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. The Company's pipeline is highlighted below: Aridis' Pipeline AR-301 (VAP). AR-301 is a fully human IgG1 mAb targeting gram-positive Staphylococcus aureus (S. aureus) alpha-toxin and is being evaluated in a global Phase 3 clinical study as an adjunctive treatment of S. aureus ventilator associated pneumonia (VAP). AR-320 (VAP). AR-320 is a fully human IgG1 mAb targeting S. aureus alpha-toxin that is being developed as a preventative treatment of S. aureus colonized mechanically ventilated patients who do not yet have VAP. Phase 3 is expected to be initiated in 2Q22. AR-501 (cystic fibrosis). AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis patients. This program is currently in Phase 2a clinical development in CF patients. AR-701 (COVID-19). AR-701 is a cocktail of fully human mAbs discovered from convalescent COVID-19 patients that are directed at multiple protein epitopes on the SARS-CoV-2 virus. It is formulated for delivery via intramuscular injection or inhalation using a nebulizer. AR-701 replaces AR-712 as the company's leading COVID mAb candidate. AR-401 (blood stream infections). AR-401 is a fully human mAb preclinical program aimed at treating infections caused by gram-negative Acinetobacter baumannii. AR-101 (HAP). AR-101 is a fully human immunoglobulin M, or IgM, mAb in Phase 2 clinical development targeting Pseudomonas aeruginosa (P. aeruginosa) liposaccharides serotype O11, which accounts for approximately 22% of all P. aeruginosa hospital acquired pneumonia cases worldwide. AR-201 (RSV infection). AR-201 is a fully human IgG1 mAb out-licensed preclinical program aimed at neutralizing diverse clinical isolates of respiratory syncytial virus (RSV).
ALong
by BADQOMOCAWGOWLD
1